Approximately one half of the hypertensives seen in primary care meet the trial entry criteria. The higher percentage of those that would qualify who were identified in this study reflects the fact that our study found many more patients with hypertension than would be detected in the average general practice population.
Hypertension was highly prevalent in this population sample. The prevalence of hypertension increases with age. The prevalence of hypertension is higher, although not yet statistically significant, among blacks and non-Hispanic whites than among Hispanics and Hispanics of Anglo/White race.
Hypertension is a common disease that, due to the fact that the disease is age-related, is a long-term problem that can last up to the age of over 70 years.\n
A number of treatments options for hypertension are common to the general population. These include both medications (i.e. ACE inhibitor, calcium-channel blocker, diuretic, glucosamine, diuretic, nitrate, ACE inhibitor, calcium-channel blocker, or a beta-blocker), supplements, and medical foods tailored for hypertensive subjects (i.e. sodium restriction, low-sodium diet, or salt sensitivity products). Many treatments for hypertension have been proven by randomized controlled trials to be safe and confer significant benefit. Many of these treatments are relatively safe and cost-effective with no adverse effect on patient morbidity or mortality.
The causes of hypertension are multiple and include excessive renin activity, vasoconstriction of the sympathetic nervous system, and aldosterone secretion. Most people with hypertension also have hypertension and/or obesity with or without comorbidities and in many cases, the cause is unknown.
We can not state that a cure has been confirmed in the light of the data evaluated here. On the other hand, we suppose that it looks likely that the possibility of curing hypertension is possible. More prospective investigations should be performed with a better selection criterion of prospective patients with the help of more elaborate studies.
Hypertension is associated with several common signs, such as nasal congestion, dizziness and fatigue. These symptoms contribute to patient distress and may adversely affect quality of life.
Quartet LDqt may relieve pain, but for many people it hasn’t been shown to prevent or treat other symptoms of high blood pressure. There is a lack of information on side effects. There have been no long term studies done on quartet LDqt in the long term. There are currently few studies on quartet LDqt which only tested for short term pain. There are very few studies which explain how it was developed, and it is only on the market for 6 years, so the evidence base for it is very weak.
Hypertension is most common among people with diabetes mellitus, with obesity, and those with other medical conditions not usually seen with hypertension. I am not aware of any compelling evidence that establishes the superiority of one treatment over another for primary hypertension.
The frequent adverse events of Quartet LDQ are gastrointestinal such as nausea, vomiting, itch, diarrhea and constipation, and some general symptoms such as insomnia, restlessness and dizziness. The most common side effect is neutropenia. It is advised that patients, particularly those who are taking antimalarial drugs, who complain of fever and myalgia be investigated for evidence of malignancy. It is reported that in some cases a prolonged QT interval can be observed when patients take one of the components of Quartet (for example, atorvastatin, clopidogrel, etc.). Therefore, patients should be informed of this possible side effect.
Recent advances from the NIH/NHLBI were highlighted which involved the development of novel therapeutic targets like the SGLT (sodium glucose cotransporter)1. The new therapeutic drug discovery platforms are a potentially valuable asset to current treatment of hypertension because of their flexibility in pharmacology, tolerability, ease of synthesis and their lack of interaction with other treatment options in antihypertensive therapy like SGLT2 (sodium glucose cotransporters) inhibitors and the other therapeutics like calcium channel antagonists.
This was a pilot study which demonstrated that quartet ldqt may be of benefit, at a low cost, in the management of patients with mild to moderate hypertension. The effect size, on HRQoL, was small. On this basis, further research, in the context of a larger clinical trial, is needed to establish a final conclusion.